Skip to content
2000
Volume 20, Issue 4
  • ISSN: 1574-8855
  • E-ISSN: 2212-3903

Abstract

Background

Pregnant women may experience low back pain and other pain symptoms, fever, and inflammatory conditions that may harm the fetus and mother if left untreated. The most common uses of non-steroidal anti-inflammatory drugs (NSAIDs) are the treatment of inflammation, pain and pyrexia. However, after 20-30 weeks of gestation, using NSAIDs during pregnancy may cause oligohydramnios and premature ductus arteriosus closure, which could harm the developing fetus.

Objectives

The purpose of this review article is to critically examine the clinical evidence that is currently available for oligohydramnios and premature ductus arteriosus closure linked to NSAIDs.

Methods

Online databases such as Medline/Pubmed/PMC, EBSCOhost, Scopus, Web of science, Embase, Science Direct, Google Scholar, and reference lists were searched to identify articles which dealt with NSAIDs-associated oligohydramnios and premature closure of ductus arteriosus.

Results

Numerous regulatory agencies released warnings about oligohydramnios and premature closure of ductus arteriosus linked to NSAIDs. Furthermore, a number of case reports, case series, and some observational studies have also been published about the possibility of oligohydramnios and premature closure of ductus arteriosus linked to NSAIDs use.

Conclusion

Women who are pregnant for 20 weeks or more should refrain from self-medicating with NSAIDs without consulting a pharmacist or a physician. The use of NSAIDs during pregnancy should carefully be considered due to potential risks to the mother and developing fetus, especially after 20-30 weeks of gestation. To guarantee the best possible health for the expectant mother and the unborn child, healthcare professionals should weigh the benefits and risks and look into alternate options. Pregnant women may opt for acetaminophen (paracetamol) to relieve pain and fever during pregnancy. Pregnant women should seek medical attention if there is persisting pain for more than three days.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdth/10.2174/0115748855308697240409035903
2024-04-24
2025-10-03

  • From This Site

    /content/journals/cdth/10.2174/0115748855308697240409035903
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. DayR.O. GrahamG.G. Non-steroidal anti-inflammatory drugs (NSAIDs).BMJ2013346f3195 23757736
     [Google Scholar]
  2. WongrakpanichS. WongrakpanichA. MelhadoK. RangaswamiJ. A comprehensive review of non-steroidal anti-inflammatory drug use in the elderly.Aging Dis.20189114315010.14336/AD.2017.0306 29392089
     [Google Scholar]
  3. HasanM. Spectrophotometric Investigations of Some Non-steroidal anti-inflammatory drugs (NSAIDs): A Brief Review.Octahedron Drug Research202310.21608/odr.2023.209154.1026
     [Google Scholar]
  4. JahnaviK. PavaniR.P. VasudhaB. NarenderB. Non-steroidal anti-inflammatory drugs: An overview.J. Drug Deliv. Ther.201991-s44244810.22270/jddt.v9i1‑s.2287
     [Google Scholar]
  5. BottingR. COX-1 and COX-3 inhibitors.Thromb. Res.20031105-626927210.1016/S0049‑3848(03)00411‑0 14592546
     [Google Scholar]
  6. SimmonsD.L. BottingR.M. HlaT. Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition.Pharmacol. Rev.200456338743710.1124/pr.56.3.3 15317910
     [Google Scholar]
  7. OsafoN AgyareC ObiriDD AntwiAO Mechanism of action of nonsteroidal anti-inflammatory drugs.Nonsteroidal anti-inflammatory drugs.201711510.5772/68090
     [Google Scholar]
  8. TaiF.W.D. McAlindonM.E. Non-steroidal anti-inflammatory drugs and the gastrointestinal tract.Clin. Med. (Lond.)202121213113410.7861/clinmed.2021‑0039 33762373
     [Google Scholar]
  9. VargaZ. SabzwariS.R.A. VargovaV. Cardiovascular risk of nonsteroidal anti-inflammatory drugs: an under-recognized public health issue.Cureus201794e1144 28491485
     [Google Scholar]
  10. HarirforooshS. JamaliF. Renal adverse effects of nonsteroidal anti-inflammatory drugs.Expert Opin. Drug Saf.20098666968110.1517/14740330903311023 19832117
     [Google Scholar]
  11. WooS.D. LuuQ.Q. ParkH.S. NSAID-exacerbated respiratory disease (NERD): from pathogenesis to improved care.Front. Pharmacol.202011114710.3389/fphar.2020.01147 32848759
     [Google Scholar]
  12. DatheK. SchaeferC. The use of medication in pregnancy.Dtsch. Arztebl. Int.201911646783790 31920194
     [Google Scholar]
  13. JinJ. Safety of medications used during pregnancy.JAMA2022328548610.1001/jama.2022.8974 35916845
     [Google Scholar]
  14. ShahS BanhET KouryK BhatiaG NandiR GulurP Pain management in pregnancy: multimodal approaches.Pain management in pregnancy: multimodal approaches.2015201510.1155/2015/987483
     [Google Scholar]
  15. EgloffC. SibiudeJ. CouffignalC. MandelbrotL. PiconeO. Causes and consequences of fever during pregnancy: A retrospective study in a gynaecological emergency department.J. Gynecol. Obstet. Hum. Reprod.202049910189910.1016/j.jogoh.2020.101899 32853830
     [Google Scholar]
  16. HanV.X. PatelS. JonesH.F. Maternal acute and chronic inflammation in pregnancy is associated with common neurodevelopmental disorders: a systematic review.Transl. Psychiatry20211117110.1038/s41398‑021‑01198‑w 33479207
     [Google Scholar]
  17. FältmarchS. PerttiläI. TuomiU. Use of opioids during pregnancy and effects of pregnancy outcomes.Pharmacoepidemiol. Drug Saf.20192891239124510.1002/pds.4848 31286617
     [Google Scholar]
  18. AsdjodiS RubarthRB HardyJ LeeH The effects of opioids during pregnancy: A literature review.Georgetown Med Rev20204110.52504/001c.16759
     [Google Scholar]
  19. ChoiE.Y. JeongH.E. NohY. Neonatal and maternal adverse outcomes and exposure to nonsteroidal anti-inflammatory drugs during early pregnancy in South Korea: A nationwide cohort study.PLoS Med.2023202e100418310.1371/journal.pmed.1004183 36848338
     [Google Scholar]
  20. WeintraubA. MankutaD. Dipyrone-induced oligohydramnios and ductus arteriosus restriction.Isr. Med. Assoc. J.2006810722723 17125127
     [Google Scholar]
  21. United States Food and Drug AdministrationDrug Safety and Availability. FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later because they can result in low amniotic fluid. NSAIDs may cause rare kidney problems in unborn babies.Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-avoiding-use-nsaids-pregnancy-20-weeks-or-later-because-they-can-result-low-amniotic (Accessed on: Dec 21, 2023).
  22. Health CanadaRecalls and safety alerts. Labelling update regarding the use of non-steroidal anti-inflammatory drugs (NSAIDs) beyond 20 weeks of pregnancy and risk of kidney damage to unborn babies.Available from: https://recalls-rappels.canada.ca/en/alert-recall/labelling-update-regarding-use-non-steroidal-anti-inflammatory-drugs-nsaids-beyond-20 (Accessed on: Dec 22, 2023).
  23. New Zealand Medicines and Medical Devices Safety AuthorityPrescriber Update. Non-steroidal anti-inflammatory drugs (NSAIDs): avoid use in pregnancy.Available from: https://medsafe.govt.nz/profs/PUArticles/September2022/Non-steroidal-anti-inflammatory%20drugs-NSAIDs-avoid-use%20in-pregnancy.html (Accessed on: Dec 25, 2023).
  24. United Kingdom Medicines & Healthcare products Regulatory Agency. Drug Safety Update. Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy.Available from: https://www.gov.uk/drug-safety-update/non-steroidal-anti-inflammatory-drugs-nsaids-potential-risks-following-prolonged-use-after-20-weeks-of-pregnancy (Accessed on: Dec 22, 2023).
  25. DatheK. FrankJ. PadbergS. HultzschS. BeckE. SchaeferC. Fetal adverse effects following NSAID or metamizole exposure in the 2nd and 3rd trimester: an evaluation of the German Embryotox cohort.BMC Pregnancy Childbirth202222166610.1186/s12884‑022‑04986‑4 36028798
     [Google Scholar]
  26. PhadkeV. BhardwajS. SahooB. KanhereS. Maternal ingestion of diclofenac leading to renal failure in newborns.Pediatr. Nephrol.20122761033103610.1007/s00467‑012‑2114‑z 22331206
     [Google Scholar]
  27. ScherneckS. SchöpaF.L. EntezamiM. KayserA. Weber-SchoendorferC. SchaeferC. Reversible oligohydramnios in the second trimester of pregnancy in two patients with long-term diclofenac exposure.Reprod. Toxicol.201558616410.1016/j.reprotox.2015.08.002 26318712
     [Google Scholar]
  28. TopuzS. HasR. ErmişH. YildirimA. IbrahimoğluL. YükselA. Acute severe reversible oligohydramnios induced by indomethacin in a patient with rheumatoid arthritis: a case report and review of the literature.Clin. Exp. Obstet. Gynecol.20043117072 14998195
     [Google Scholar]
  29. SandruckJ.C. GrobmanW.A. GerberS.E. The effect of short-term indomethacin therapy on amniotic fluid volume.Am. J. Obstet. Gynecol.200519251443144510.1016/j.ajog.2004.12.036 15902132
     [Google Scholar]
  30. SavageA. AndersonB. SimhanH. The safety of prolonged indomethacin therapy.Am. J. Perinatol.200724420721310.1055/s‑2007‑976546 17447185
     [Google Scholar]
  31. KlauserC.K. BrieryC.M. MartinR.W. LangstonL. MagannE.F. MorrisonJ.C. A comparison of three tocolytics for preterm labor: A randomized clinical trial.J. Matern. Fetal Neonatal Med.201427880180610.3109/14767058.2013.847416 24090282
     [Google Scholar]
  32. HolmesR.P. StoneP.R. Severe oligohydramnios induced by cyclooxygenase-2 inhibitor nimesulide.Obstet. Gynecol.2000965 Pt 2810811 11094215
     [Google Scholar]
  33. PaternosterD.M. SnijdersD. ManganelliF. TorrisiA. BraccianteR. Anhydramnios and maternal thrombocytopenia after prolonged use of nimesulide.Eur. J. Obstet. Gynecol. Reprod. Biol.20031081979810.1016/S0301‑2115(02)00343‑3 12694979
     [Google Scholar]
  34. SawdyR.J. GroomK.M. BennettP.R. Experience of the use of nimesulide, a cyclo-oxygenase-2 selective prostaglandin synthesis inhibitor, in the prevention of preterm labour in 44 high-risk cases.J. Obstet. Gynaecol.200424322622910.1080/01443610410001660661 15203612
     [Google Scholar]
  35. GrincevičienėŠ. VolochovičJ. GrincevičiusJ. Lack of pharmacist–physician communication associated with nimesulide-induced oligohydramnios during pregnancy.Int. J. Clin. Pharm.201638219619810.1007/s11096‑016‑0267‑8 26951121
     [Google Scholar]
  36. CampbellS. ClohessyA. O’BrienC. HigginsS. HigginsM. McAuliffeF. Fetal anhydramnios following maternal non-steroidal anti-inflammatory drug use in pregnancy.Obstet. Med.2017102939510.1177/1753495X16686466 28680471
     [Google Scholar]
  37. IshidaH. InamuraN. KawazuY. KayataniF. Clinical features of the complete closure of the ductus arteriosus prenatally.Congenit. Heart Dis.201161515610.1111/j.1747‑0803.2010.00411.x 21269413
     [Google Scholar]
  38. EnzensbergerC. WienhardJ. WeichertJ. Idiopathic constriction of the fetal ductus arteriosus: Three cases and review of the literature.J. Ultrasound Med.20123181285129110.7863/jum.2012.31.8.1285 22837295
     [Google Scholar]
  39. GewilligM. BrownS.C. De CatteL. Premature foetal closure of the arterial duct: Clinical presentations and outcome.Eur. Heart J.200930121530153610.1093/eurheartj/ehp128 19389789
     [Google Scholar]
  40. United States Food and Drug AdministrationMedical Product Safety Information. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Drug Safety Communication - Avoid Use of NSAIDs in Pregnancy at 20 Weeks or Later.Available from: https://www.fda.gov/safety/medical-product-safety-information/nonsteroidal-anti-inflammatory-drugs-nsaids-drug-safety-communication-avoid-use-nsaids-pregnancy-20 (Accessed on: Dec 27, 2023)
     [Google Scholar]
  41. TanakaS. HoriS. SatohH. SawadaY. Prediction of fetal ductus arteriosus constriction by systemic and local dermatological formulations of NSAIDs based on PK/PD analysis.Int. J. Clin. Pharmacol. Ther.2016541078279410.5414/CP202532 27285464
     [Google Scholar]
  42. TanakaS. KanagawaT. MommaK. Prediction of sustained fetal toxicity induced by ketoprofen based on PK/PD analysis using human placental perfusion and rat toxicity data.Br. J. Clin. Pharmacol.201783112503251610.1111/bcp.13352 28635050
     [Google Scholar]
  43. KorenG. FlorescuA. CosteiA.M. BoskovicR. MorettiM.E. Nonsteroidal antiinflammatory drugs during third trimester and the risk of premature closure of the ductus arteriosus: A meta-analysis.Ann. Pharmacother.200640582482910.1345/aph.1G428 16638921
     [Google Scholar]
  44. LopesL.M. CarrilhoM.C. FranciscoR.P.V. LopesM.A.B. KrebsV.L.J. ZugaibM. Fetal ductus arteriosus constriction and closure: Analysis of the causes and perinatal outcome related to 45 consecutive cases.J. Matern. Fetal Neonatal Med.201629463864510.3109/14767058.2015.1015413 25708490
     [Google Scholar]
  45. SiuK.L. LeeW.H. Maternal diclofenac sodium ingestion and severe neonatal pulmonary hypertension.J. Paediatr. Child Health200440315215310.1111/j.1440‑1754.2004.00319.x 15009583
     [Google Scholar]
  46. AuerM. BrezinkaC. EllerP. LuzeK. SchweigmannU. SchwärzlerP. Prenatal diagnosis of intrauterine premature closure of the ductus arteriosus following maternal diclofenac application.Ultrasound Obstet. Gynecol.200423551351610.1002/uog.1038 15133806
     [Google Scholar]
  47. ShastriA.T. AbdulkarimD. ClarkeP. Maternal diclofenac medication in pregnancy causing in utero closure of the fetal ductus arteriosus and hydrops.Pediatr. Cardiol.20133481925192710.1007/s00246‑012‑0461‑y 22872018
     [Google Scholar]
  48. AkerK. BrantbergA. NyrnesS.A. Prenatal constriction of the ductus arteriosus following maternal diclofenac medication in the third trimester.Case Reports2015201510.1136/bcr‑2015‑210473
     [Google Scholar]
  49. NdourD.D. [Maternal use of non-steroidal antiinflammatory drugs and closure of the ductus arteriosus].Pan Afr. Med. J.201625251 28293367
     [Google Scholar]
  50. dos SantosC.S. SilvaP.V. CasteloR. TiagoJ. Premature closure of ductus arteriosus after a single dose of diclofenac during pregnancy.BMJ Case Rep.2021146e24348510.1136/bcr‑2021‑243485 34167992
     [Google Scholar]
  51. dos SantosC.S. SilvaP.V. CasteloR. TiagoJ. Premature closure of ductus arteriosus after a single dose of diclofenac during pregnancy.Drug Ther. Bull.2022601117017510.1136/dtb.2022.243485rep 36302541
     [Google Scholar]
  52. TorloniM.R. CordioliE. ZamithM.M. Reversible constriction of the fetal ductus arteriosus after maternal use of topical diclofenac and methyl salicylate.Ultrasound Obstet. Gynecol.200627222722910.1002/uog.2647 16355417
     [Google Scholar]
  53. Le DucK. GilliotS. BaudeletJ.B. Case report: Persistent pulmonary hypertension of the newborn and narrowing of the ductus arteriosus after topical use of non-steroidal anti-inflammatory during pregnancy.Front. Pharmacol.20211275605610.3389/fphar.2021.756056 34899309
     [Google Scholar]
  54. PaladiniD. MarasiniM. VolpeP. Severe ductal constriction in the third‐trimester fetus following maternal self‐medication with nimesulide.Ultrasound Obstet. Gynecol.200525435736110.1002/uog.1873 15791693
     [Google Scholar]
  55. PrefumoF. MarasiniM. De BiasioP. VenturiniP.L. Acute premature constriction of the ductus arteriosus after maternal self-medication with nimesulide.Fetal Diagn. Ther.2008241353810.1159/000132403 18504378
     [Google Scholar]
  56. GeramiR. FarajnejadG.K. RoudbariS. Early ductus arteriosus constriction: A rare case presentation at 18 weeks of gestation.Int. J. Pediatr.2020881186111866
     [Google Scholar]
  57. SchiesslB. SchneiderK.T. ZimmermannA. KainerF. FrieseK. OberhofferR. Prenatal constriction of the fetal ductus arteriosus--related to maternal pain medication?Z. Geburtshilfe Neonatol.20052092656810.1055/s‑2005‑864116 15852232
     [Google Scholar]
  58. AminS.B. SinkinR.A. GlantzJ.C. Metaanalysis of the effect of antenatal indomethacin on neonatal outcomes.Am. J. Obstet. Gynecol.20071975486.e1486.e1010.1016/j.ajog.2007.04.019 17980183
     [Google Scholar]
  59. HammersA.L. Sanchez-RamosL. KaunitzA.M. Antenatal exposure to indomethacin increases the risk of severe intraventricular hemorrhage, necrotizing enterocolitis, and periventricular leukomalacia: a systematic review with metaanalysis.Am. J. Obstet. Gynecol.20152124505.e1505.e1310.1016/j.ajog.2014.10.1091 25448524
     [Google Scholar]
  60. Pakkir MaideenN.M. BarakatI.R. JumaleA.H. Paracetamol (Acetaminophen)-associated SJS, TEN, AGEP, and DRESS syndromes-A narrative review.Curr. Drug Saf.202419221822310.2174/1574886318666230505144014 37151075
     [Google Scholar]
  61. DatheK. FrankJ. PadbergS. Negligible risk of prenatal ductus arteriosus closure or fetal renal impairment after third‐trimester paracetamol use: Evaluation of the German Embryotox cohort.BJOG2019126131560156710.1111/1471‑0528.15872 31310697
     [Google Scholar]
  62. CzeizelA.E. DudásI. PuhóE. Short‐term paracetamol therapy during pregnancy and a lower rate of preterm birth.Paediatr. Perinat. Epidemiol.200519210611110.1111/j.1365‑3016.2005.00631.x 15787885
     [Google Scholar]
  63. ArnejaJ. HungR.J. SeetoR.A. Association between maternal acetaminophen use and adverse birth outcomes in a pregnancy and birth cohort.Pediatr. Res.20208771263126910.1038/s41390‑019‑0726‑8 31852009
     [Google Scholar]
  64. de CastroC.T. PereiraM. dos SantosD.B. Association between paracetamol use during pregnancy and perinatal outcomes: Prospective NISAMI cohort.PLoS One2022174e026727010.1371/journal.pone.0267270 35436308
     [Google Scholar]
  65. CastroC.T. GamaR.S. PereiraM. Effect of Acetaminophen use during pregnancy on adverse pregnancy outcomes: A systematic review and meta-analysis.Expert Opin. Drug Saf.202221224125110.1080/14740338.2022.2020246 34964403
     [Google Scholar]
/content/journals/cdth/10.2174/0115748855308697240409035903
Loading
Oligohydramnios and Intrauterine Premature Closure of Ductus Arteriosus Associated with the Use of NSAIDs During Pregnancy – An Overview of Clinical Evidence
Curr Drug Ther 20, 554 (2025); https://doi.org/10.2174/0115748855308697240409035903
/content/journals/cdth/10.2174/0115748855308697240409035903
/content/journals/cdth/10.2174/0115748855308697240409035903
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): adverse drug effects; contraindication; Non-steroidal anti-inflammatory drugs; NSAIDs; oligohydramnios; pregnancy; premature closure of ductus arteriosus

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test